To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

PresentationArthur SandsCEO, President & Director Good morning, and welcome to the Nurix Therapeutics Conference Call. I'm Arthur Sands, President and CEO. And I'm joined today on this call by Gwenn Hansen, our Chief Scientific Officer; Paula O'Connor, our Chief Medical Officer; and Hans Van Houte, our Chief Financial Officer. These are our disclaimers. At Nurix, we're advancing a pipeline of innovative targeted protein degrader drugs in oncology and inflammation and immunology or I&I, each with best-in-cl ...

Summary of Nurix Therapeutics Conference Call (October 22, 2025) Company Overview - **Company**: Nurix Therapeutics (NasdaqGM:NRIX) - **Focus**: Development of targeted protein degrader drugs in oncology and inflammation/immunology (INI) with best-in-class potential Key Points on Lead Program: Vexer-Brutideg (NX-5948) - **Clinical Development**: - Initiation of pivotal trials in Chronic Lymphocytic Leukemia (CLL) has been announced, with regulatory alignment on dose selection for registrational purposes achieved with the FDA and other global authorities [4][5][39] - The selected dose for registrational trials is 600 mg once daily, based on favorable safety profiles observed in phase 1 studies [5][6] - The first pivotal trial, named the Daybreak study, is a single-arm phase 2 study targeting approximately 100 patients with relapsed refractory CLL [6][19] - **Efficacy Data**: - Objective response rate (ORR) of 80.9% observed in patients with high unmet medical need, including those with TP53 and/or BTK mutations [15][66] - Median time to response is less than two months, with durable treatment effects noted [16][17] - **Mechanism of Action**: - Vexdeg is effective against wild-type BTK and clinically relevant BTK mutations, addressing both the scaffolding function of BTK and promoting tumor cell growth [8][9] - Demonstrates catalytic action, degrading 10,000 to 20,000 BTK proteins per hour, which is a significant advantage over traditional inhibitors [8] - **Regulatory Designations**: - Vexdeg has received fast-track status in the U.S. and PRIME designation in the EU, facilitating expedited development [4][12] Pipeline Developments - **Partnerships**: - Nurix has partnered with Sanofi for the STAT-6 program and Gilead Sciences for the IRAK4 program, with potential for co-development in the U.S. [2][32] - New preclinical data for both partnered programs has been disclosed, highlighting their differentiation potential [2][32] - **Future Studies**: - A confirmatory phase 3 trial is planned for the first half of 2026, targeting a broader patient population [20][39] - Combination studies with other agents are also being explored to enhance patient outcomes [21] Financial Position - **Cash Position**: - Nurix anticipates a pro forma cash balance of $678 million, providing a runway into 2028 [39] Market Context - **CLL Market**: - Approximately 120,000 patients initiate new treatment each year across major markets, with 50% in the second line or later [18] - The company aims to address the needs of relapsed and refractory CLL patients, particularly those who are triple-exposed to existing therapies [19][61] Competitive Landscape - **Differentiation**: - Vexdeg is positioned as a potentially best-in-class BTK degrader, with superior potency, mutation coverage, and selectivity compared to existing therapies [25][26][76] - The market for degraders is expected to be large, with potential for multiple drugs to coexist, but Nurix believes Vexdeg will capture significant market share due to its profile [76] Conclusion - Nurix Therapeutics is advancing its lead program Vexer-Brutideg towards pivotal trials in CLL, with promising efficacy data and strong regulatory support. The company is well-positioned financially and strategically to capitalize on the growing market for targeted protein degraders in oncology and inflammation.

Bexobrutideg Investor Update Investor Presentation October 2025 Certain information contained in this presentation relates to or is based on studies, publications, surveys and other data obtained from third-party sources and the Company's own internal estimates and research. While the Company believes these third-party sources to be reliable as of the date of this presentation, it has not independently verified, and makes no representation as to the adequacy, fairness, accuracy or completeness of, any infor ...

SAN FRANCISCO, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines in oncology and autoimmune disease, today announced the pricing of its underwritten registered offering of 24,485,799 shares of its common stock at a price of $10.21 per share. The gross proceeds to Nurix from the offering, before deducting underwriting discounts and commissio ...

600 mg once daily bexobrutideg oral dose cleared by global regulators for pivotal monotherapy trials in relapsed/refractory chronic lymphocytic leukemia (r/r CLL) Phase 2 DAYBreak trial initiated for potential Accelerated Approval New preclinical data support bexobrutideg as potential best-in-class BTK degrader profile Nurix will host an investor webcast today, Wednesday, October 22nd, at 8:00 a.m. EDT SAN FRANCISCO, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage ...

Core Insights - NX-1607 is a first-in-class oral inhibitor of CBL-B, demonstrating on-target peripheral immune activation and anti-tumor activity in heavily pretreated patients with advanced solid tumors [1][2][4] - The clinical data presented at ESMO 2025 supports the initiation of expansion cohorts for further evaluation of NX-1607 as a monotherapy or in combination therapies [1][2] Company Overview - Nurix Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on targeted protein degradation medicines, aiming to improve treatment options for cancer and inflammatory diseases [7] - The company is advancing multiple clinical and preclinical programs, including NX-1607 and bexobrutideg, an oral BTK degrader [7] Clinical Data Summary - In a Phase 1a study, 82 patients with various solid tumors were treated with NX-1607 across different dosing regimens, showing a disease control rate (DCR) of 49.3% [2][3] - Notable clinical activity included reductions in tumor-specific biomarkers, long-term stable disease, and a confirmed partial response in a patient with micro-satellite stable colorectal cancer [2][3] - The most significant reductions in prostate-specific antigen (PSA) were observed in patients receiving BID dosing, with 6 out of 13 patients achieving PSA reductions of ≥50% [2] Safety Profile - NX-1607 exhibited a tolerable safety profile, comparable to approved immuno-oncology agents, with most adverse events being Grade 2 or less [3] - Immune-related adverse events were observed in 6 patients, indicating on-target immune activation similar to PD-1/PD-L1 therapies [3] Future Development - The company plans to further explore the therapeutic potential of NX-1607, particularly in indications where current immunotherapies have shown limited efficacy, such as MSS colorectal cancer and metastatic prostate cancer [4]

Core Insights - NX-1607 is a first-in-class oral inhibitor of CBL-B, demonstrating on-target peripheral immune activation and anti-tumor activity in heavily pretreated patients with advanced solid tumors [1][2][4] - The clinical data presented at ESMO 2025 supports the initiation of expansion cohorts for further evaluation of NX-1607 as a monotherapy or in combination therapies [1][2] Company Overview - Nurix Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on targeted protein degradation medicines, aiming to improve treatment options for cancer and inflammatory diseases [7] - The company is advancing multiple clinical and preclinical programs, including NX-1607 and bexobrutideg, an oral BTK degrader [7] Clinical Data Summary - In a Phase 1a study, 82 patients with various solid tumors were treated with NX-1607 across different dosing regimens, showing dose-dependent exposure and clinical activity [2][3] - The disease control rate (DCR) was reported at 49.3%, with notable reductions in tumor-specific biomarkers such as PSA and CEA [2][3] - The treatment was well-tolerated, with most adverse events being Grade 2 or less, and immune-related adverse events indicating on-target immune activation [3][4] Therapeutic Potential - NX-1607 targets a previously unaddressed pathway in immune regulation, affecting multiple immune cell types, which may enhance its efficacy in treating solid tumors [2][6] - The results are particularly promising for tumor types like micro-satellite stable colorectal cancer and metastatic prostate cancer, where current immunotherapies have shown limited efficacy [4]

Core Insights - Nurix Therapeutics is focused on developing innovative therapies for cancer treatment, particularly its oral BTK degrader, bexobrutideg, targeting chronic lymphocytic leukemia (CLL) [1][5] - The company plans to initiate a pivotal phase 2 study in late 2025, indicating a strong commitment to advancing its clinical programs [1][5] Financial Summary - Stifel Nicolaus has set a price target of $33 for NRIX, suggesting a potential upside of approximately 238% from its current price of $9.76 [2][5] - The stock has experienced a decrease of 10.13%, reflecting market volatility, while the company's market capitalization stands at $750.3 million [2] Clinical Data - Nurix's phase 1a data for bexobrutideg shows an impressive 80.9% overall response rate (ORR), supporting the potential for Accelerated Approval [3][5] - The company aims to expand its efforts with a phase 3 trial and explore combination therapies for CLL, targeting a multibillion-dollar market [3][5] Stock Performance - The stock has fluctuated between $9.50 and $10.56 today, with a 52-week high of $29.56 and a low of $8.18, indicating active investor interest [4] - Trading volume stands at 1,996,408 shares, suggesting significant market activity [4]

Nurix Therapeutics, Inc. (NASDAQ:NRIX) reported an earnings per share (EPS) of -$1.03, missing the estimated EPS of -$0.91, marking a significant increase from the $0.67 loss per share in the same quarter last year.The company's revenue for the quarter was $7.89 million, falling short of the estimated $13.27 million, representing a 57.71% miss from the Zacks Consensus Estimate.Despite financial challenges, NRIX maintains a strong current ratio of 5.35 and a low debt-to-equity ratio of 0.15, indicating good ...